b'and file for authorization in late January or February. Novavax also expects wrap up its trials and submit its application to the FDA in the first quarter of 2021. Sanofi-GlaxoSmithKlinesvaccinewilllikelybe ready in the second half of the year.Throughout the vaccine development and distribu-tion process, Weve seen unprecedented levels of collaboration between the government and industry on behalf of the American people, said Army Brig. Gen.MichaelMacMcCurry,OperationWarp Speeds deputy for security and assurance.Beyond VaccinesAt the end of December, Operation Warp Speed agreed to support the advanced development and large-scalemanufacturingofMercksinvesti-gational therapeutic MK-7110 for the treatment ofhospitalizedpatientswithsevereorcritical COVID-19. MK-7110 represents a first-in-class fusionproteinandimmunemodulatorthatthe company hopes can rein in an excessive immuneStaff Sgt. Michael Elbo administers a COVID-19 vaccine at Whiteman Air Force response cascade, limiting the damage to organs. Base, MO, on New Years Eve 2020. Operation Warp Speeds partnerships The agreement provided $356 to Merck to takewith industry helped make vaccines available as soon as possible.thepotentialtherapeuticthroughclinicaltrials,Air Force photo by Tech. Sgt. Alexander W. Riedelsubmission to the FDA and delivery of 100,000 dosesbyJune30,2021,pendinggrantingofemer- how industry and government are coming together under gencyuseauthorization.Aswiththevaccines,theOperation Warp Speed to move potential therapeutics all upfront money will enable Merck to ramp up produc- thewayfromdevelopmentthroughtomanufacturing, tion of MK-7110 prior to the FDAs decision.enabling faster distribution, Azar said.BasedonearlyresultsofaPhase3clinicaltrial,At the end of the year, the U.S. Army announced another MK-7110 has a good chance of receiving authorization pandemic-related collaboration. The U.S. Army Medical itincreasedthechanceofclinicalrecovery60%ResearchandDevelopmentCommand(USAMRDC) comparedtoplaceboandcuttheriskofrespiratoryfunded a clinical trial of the BioIntelliSense BioSticker failure or death by 50% compared to current standarddeviceforearlydetectionofCOVID-19symptoms of care. combinedwithPhilipsremotepatientmonitoring Our agreement with Merck is the latest example ofplatform.Keyindustryandacademicpartnershipsprovide DoDatimelyopportunitytofieldmedical-grade Operation Warp Speed, thewearablescapableofhigh-frequencyphysiologic surveillance, stated Commander Christopher Steele, U.S. governments joint effortPhD, director of the Military Operational Medicine ResearchProgramatUSAMRDC.Ourgoalsare of the Department of Humanto capitalize on mature, wearable tech and validate predictive algorithms to identify COVID-19 positive Services (HHS) and the DoD,individualsthathaveyettoshowclearmedical symptoms.Outputscandirectlymaximizemilitary invested in industry partnershipspreparedness and provide immediate benefit for the general population as these tools can be used outside to bring vaccines to fruition asof medical treatment facilities.quickly as possible. THE VALUE OF THE PARTNERSHIP: Industry and the Federal Customer Working Together 9'